GlassScriptPhysician profile
William Loomis Pomeroy
NPI 1548458367
$3,484.09
in general payments reported to CMS, 2019-2025
19 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $14.59 · 2021: $114 · 2022: $453 · 2023: $626 · 2024: $871 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,760.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,281.12 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $875.19 | 2021-2025 | |
| Novo Nordisk INC | $266.53 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $196.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $157.11 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $139.46 | 2024-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.44 | 2023-2025 | Jardiance |
| Abiomed | $122.60 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $106.14 | 2025 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $46.43 | 2025 | |
| Abbott Laboratories | $35.32 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.73 | 2019 | |
| Sunovion Pharmaceuticals INC. | $30.64 | 2019-2020 | |
| Boston Scientific Corporation | $19.73 | 2025 | Watchman Flx |
| Medtronic Vascular, INC. | $18.90 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.19 | 2025 | Lifevest |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pomeroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.